proprietary microarray platform (Epigenomics ag)
90
Structured Review
Epigenomics ag
proprietary microarray platform
![Determination of PITX2 cut-off points and Kaplan Meier analysis. ( a) Statistical analysis of PITX2 cut-off points (PMR) for all patients (n = 204). <t>Microarray</t> gLOG data were converted with 2exp(gLOG) function to calculated PITX2 PMR data (PMR calc ); x-axis: Calculated PITX2 PMR data [%]; y-axis: Standardized log-rank statistics. Dashed vertical line marks the maximum cut-off point of PITX2 PMR calc at 14.73. ( b) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) using the maximum PITX2 cut-off point (PMR calc = 14.73). Patients were treated with anthracycline-based chemotherapy ± endocrine therapy (HR 2.321; p < 0.001). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( c) Kaplan-Meier analysis for DFS of subgroup of high-risk breast cancer patients treated with anthracycline-based chemotherapy and additional endocrine therapy (n = 96) using the maximum PITX2 cut-off point (PMR calc = 14.73) (HR 2.285; p = 0.024). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( d) Statistical evaluation of PITX2 DNA percent methylation ratio (PMR) cut-off points. PMR data (n = 204) are equivalent (PMR equiv ) to therascreen PITX2 RGQ PCR assay determined PMR values. x-axis: equivalent PITX2 PMR [%]; y-axis: Standardized log-rank statistics. The dashed vertical line marks the maximum log-rank statistic at a PITX2 PMR cut-off point of 12. ( e) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) treated with anthracycline-based chemotherapy ± endocrine therapy using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 2.478; p < 0.001). Upper line: PMR ≤ 12. Lower line: PMR > 12. ( f) Kaplan-Meier analysis for DFS of high-risk breast cancer patients treated with anthracycline-based chemotherapy plus endocrine therapy (n = 96) using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 3.057; p = 0.002). Upper line: PMR ≤ 12. Lower line: PMR > 12. Kaplan-Meier analysis: n = 2 patients with DFS at 147 and 166 months were censored for DFS analysis with follow-up time of 120 months.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7923/pmc06237923/pmc06237923__41598_2018_34919_Fig2_HTML.jpg)
Proprietary Microarray Platform, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+platform/pmc06237923-60-4-11?v=Epigenomics+ag
Average 90 stars, based on 1 article reviews
Proprietary Microarray Platform, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+platform/pmc06237923-60-4-11?v=Epigenomics+ag
Average 90 stars, based on 1 article reviews
proprietary microarray platform - by Bioz Stars,
2026-08
90/100 stars
Images
1) Product Images from "Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer"
Article Title: Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
Journal: Scientific Reports
doi: 10.1038/s41598-018-34919-1
Figure Legend Snippet: Determination of PITX2 cut-off points and Kaplan Meier analysis. ( a) Statistical analysis of PITX2 cut-off points (PMR) for all patients (n = 204). Microarray gLOG data were converted with 2exp(gLOG) function to calculated PITX2 PMR data (PMR calc ); x-axis: Calculated PITX2 PMR data [%]; y-axis: Standardized log-rank statistics. Dashed vertical line marks the maximum cut-off point of PITX2 PMR calc at 14.73. ( b) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) using the maximum PITX2 cut-off point (PMR calc = 14.73). Patients were treated with anthracycline-based chemotherapy ± endocrine therapy (HR 2.321; p < 0.001). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( c) Kaplan-Meier analysis for DFS of subgroup of high-risk breast cancer patients treated with anthracycline-based chemotherapy and additional endocrine therapy (n = 96) using the maximum PITX2 cut-off point (PMR calc = 14.73) (HR 2.285; p = 0.024). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( d) Statistical evaluation of PITX2 DNA percent methylation ratio (PMR) cut-off points. PMR data (n = 204) are equivalent (PMR equiv ) to therascreen PITX2 RGQ PCR assay determined PMR values. x-axis: equivalent PITX2 PMR [%]; y-axis: Standardized log-rank statistics. The dashed vertical line marks the maximum log-rank statistic at a PITX2 PMR cut-off point of 12. ( e) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) treated with anthracycline-based chemotherapy ± endocrine therapy using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 2.478; p < 0.001). Upper line: PMR ≤ 12. Lower line: PMR > 12. ( f) Kaplan-Meier analysis for DFS of high-risk breast cancer patients treated with anthracycline-based chemotherapy plus endocrine therapy (n = 96) using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 3.057; p = 0.002). Upper line: PMR ≤ 12. Lower line: PMR > 12. Kaplan-Meier analysis: n = 2 patients with DFS at 147 and 166 months were censored for DFS analysis with follow-up time of 120 months.
Techniques Used: Microarray, Methylation
Figure Legend Snippet: Establishment of the transformation curve. Correlation of the PMR calc (mathematically converted microarray data) and PMR exp (data determined by therascreen PITX2 RGQ PCR assay) with 121 samples (41 ER−; 80 ER+). Coefficient factors: r-squared = 0.5219; r = 0.722.
Techniques Used: Transformation Assay, Microarray